Skip to content
1 Minute Read

CRIO Welcomes Dr. Margaretta Nyilas to its Board of Directors

 BOSTON, MA – November 3, 2022CRIO, the industry’s leading eSource provider, announces the appointment of Dr. Margaretta Nyilas to its Board of Directors, effective immediately. 

Dr. Nyilas is a biopharmaceutical executive with over twenty years of diverse global industry experience, formerly at Otsuka Pharmaceuticals, Bristol Myers Squibb and Click Therapeutics. She has a proven track record of delivering high value assets such as ABILIFY MYCITE® (aripiprazole tablets with sensors), ABILIFY MAINTENA® (aripiprazole),  REXULTI™ (brexpiprazole), and ABILIFY® (aripiprazole). 

Currently, she is serving as a director and strategic advisor for the biopharmaceutical industry and as Venture Affiliate Partner with Boston Millennia Partners. 

Throughout her career, Dr. Nyilas has championed innovation in the clinical trial process and was an early adopter of electronic source data collection. She joins CRIO as its first independent director, bringing her unique blend of knowledge in clinical operations, technology and medicine.

“We couldn’t be happier with Margaretta joining the Board,” says Raymond Nomizu, JD, CEO and co-founder at CRIO. “With over 2,000 sites using our system across thousands of studies, we are leveraging our technology to create efficiencies for sites, sponsors and CROs. As an innovator in eClinical technology, Margaretta will provide invaluable insight and guidance to position our product roadmap and vision to the needs of clinical trial sponsors.”

Dr. Nyilas joins CRIO board members Sankesh Abbhi, formerly CEO of ArisGlobal; Tom Peterson, Venture Partner at Rally Ventures; and CEO, Raymond Nomizu. Ren Roome of Boston Millennia Partners serves as a board observer.

About CRIO

CRIO is an eClinical solution provider delivering innovative data capture technology for sites, sponsors and CROs. Innovation is at the heart of everything we do. As the industry’s leading eSource provider, CRIO’s unique architecture enables a single point of data capture that embeds quality and transparency at the point of entry, and creates significant downstream efficiencies. Finally. One system. One source. Today, CRIO supports more than 2,000 medical research sites and 4,000+ protocols worldwide. For more information about CRIO, visit clinicalresearch.io.

 

by Daenya McDonald Marketing Director
Share this post
You may also find interesting
Explore our Blog
Algorics Partnership
CRIO Company News
1 Minute Read -

CRIO Announces Partnership with Algorics

CRIO is thrilled to announce an exciting partnership with Algorics! This partnership represents our continued efforts in revolutionizing the landscape of clinical trials technology. At CRIO, our commitment has always been to provide innovative solutions that drive data quality and enhance patient safety, while saving CRIO sites and sponsors both time and money. “CRIO is...

CRIO and SDC Partnership
CRIO Company News
2 Minute Read -

SDC Announces Partnership with CRIO on eSource Initiative

Boston, MA – Continuing the momentum of technology solution innovations after its recent release of SDC Insights™, SDC is proud to partner with CRIO to bring eSource functionality in-house to better serve clients and their clinical needs.  “With SDC’s in-house developers, we can efficiently meet the individual needs of each protocol with CRIO eSource, a...

Our new board of directors member Jeff Stein
CRIO Company News
1 Minute Read -

We are pleased to announce Mr. Jeffrey Stein as the newest member of CRIO’s Board of Directors!

Jeff Stein currently serves as the CEO and President of ALSA Research, which has been an early adopter of cloud-based technologies that are now standard practices across the clinical research industry. After beginning his career on Wall Street with Salomon Brothers, Jeff opened the firm’s London based MBS group. Shortly after, Jeff acquired a controlling...

Get articles delivered to your inbox, every week